Anderson Hoagland & Co. Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Anderson Hoagland & Co. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 84.2% during the fourth quarter, HoldingsChannel reports. The firm owned 535 shares of the biopharmaceutical company’s stock after selling 2,854 shares during the quarter. Anderson Hoagland & Co.’s holdings in Regeneron Pharmaceuticals were worth $365,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of REGN. Adirondack Trust Co. raised its stake in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares in the last quarter. UMB Bank n.a. grew its holdings in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Trust Co. of Vermont raised its position in Regeneron Pharmaceuticals by 8.3% in the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 12 shares in the last quarter. Nvwm LLC lifted its holdings in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on REGN shares. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 2.7 %

Shares of REGN opened at $675.79 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20. The company has a market capitalization of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The stock has a fifty day moving average of $727.19 and a two-hundred day moving average of $937.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.